Decision: Favourable

Study Title:

A phase III, multicenter, randomized, double blind, placebocontrolle study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R

  • NREC Code:

    21-NREC-CT-011

  • Decision:

    Favourable

  • Meeting Date:

    07/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    NOVARTIS Pharma AG delegated TRIO CRO

Scroll to Top
Skip to content